Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma

Core Insights - Moderna, Inc. has initiated a Phase 1/2 study for its investigational mRNA-based T-cell engager, mRNA-2808, targeting relapsed or refractory multiple myeloma [1] Company Developments - The first patient has been dosed with mRNA-2808 at SCRI Oncology Partners in Nashville, Tennessee [1] - The study is being conducted in collaboration with the Sarah Cannon Research Institute [1]